Evaluating the Pulmonary Nodule With Imaging and Biomarkers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01739881|
Recruitment Status : Unknown
Verified July 2012 by National University Hospital, Singapore.
Recruitment status was: Recruiting
First Posted : December 4, 2012
Last Update Posted : December 4, 2012
|Condition or disease||Intervention/treatment||Phase|
|Lung Cancer||Device: Olympus Ultrathin Bronchofibervideoscope (XP260F)||Not Applicable|
- To improve diagnostic yield of pulmonary nodule or mass by using combined approach of navigation bronchoscopy and EBUS.
- To determine if characteristic features of EBUS and confocal microendoscopy exist as well as VOC patterns in alveolar and exhaled gas that can aid in discriminating malignant pulmonary nodule or mass from benign etiology by correlating with pathology.
- To identify VOC patterns specific for lung cancer by correlating VOC from directly sampled alveolar gas and exhaled breath with pathology. Exhaled breath VOC signature may complement CT in screening population at risk.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluating the Pulmonary Nodule With Imaging and Biomarkers|
|Study Start Date :||April 2011|
|Estimated Primary Completion Date :||March 2013|
|Estimated Study Completion Date :||March 2013|
- Device: Olympus Ultrathin Bronchofibervideoscope (XP260F)
The bronchovideoscope will be used together with an assisted image-guided bronchoscopic navigation software system called LungPoint®, to view lungs in a real time 3D manner.Other Name: Olympus Lucera Broncho Fibervideoscope (BF-XP260F)
- Correlating pathology between EBUS, confocal microendoscopy and VOC patterns to aid in characterising malignant and benign etiology.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01739881
|Contact: Pyng Lee, MDfirstname.lastname@example.org|
|National University Hospital/ National University of Singapore||Recruiting|
|Singapore, Singapore, 119228|
|Contact: Pyng Lee, MD +65-67795555 email@example.com|
|Principal Investigator:||Pyng Lee, MD||National University Hospital, Singapore|